{"meshTagsMajor":["Breast Neoplasms","Receptor, ErbB-2"],"meshTags":["Breast Neoplasms","Receptor, ErbB-2","Female","Humans","Russia","Trastuzumab","Antibodies, Monoclonal, Humanized","Neoplasms, Hormone-Dependent","Immunohistochemistry","Reference Standards"],"meshMinor":["Female","Humans","Russia","Trastuzumab","Antibodies, Monoclonal, Humanized","Neoplasms, Hormone-Dependent","Immunohistochemistry","Reference Standards"],"genes":["HER2","HER2"],"publicationTypes":["Editorial","English Abstract"],"abstract":"The paper analyzes 10 years\u0027 experience in HER2 status testing in breast cancer in Russia. The ASCO/CAP HER2 testing guidelines adaptable to the work of pathologists in Russia are considered.","title":"[10 years of testing of the HER2 status in breast cancer in Russia].","pubmedId":"23342651"}